Latest
Mpox Vaccine Immunity Wanes After Several Months, Study Finds
A new study from Harvard Medical School has found that immunity provided by the mpox vaccine declines within months, raising concerns about the need for booster shots. The research, published in the medical journal JAMA, analyzed blood samples from 45 individuals who were either vaccinated or infected with mpox in 2022. The study revealed that antibody levels against mpox dropped significantly between six to 12 months after vaccination.
Researchers found that receiving two doses of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine—administered four weeks apart—resulted in better immunity in the short term compared to one dose. However, a year later, the immune response for those who received two shots was comparable to the peak response of individuals who had only one dose, which offered limited protection. This suggests that people vaccinated during the global 2022 mpox outbreak may need booster shots to maintain adequate immunity.
“This study suggests that boosters might be required to maintain vaccine effectiveness,” said Jonas Albarnaz, a virology and immunology researcher at the UK-based Pirbright Institute, in response to the findings.
Countries like France have already recommended mpox booster shots for high-risk groups, including gay and bisexual men, sex workers, and individuals with multiple sexual partners.
While the study highlights a decline in antibodies, experts caution that this doesn’t necessarily mean reduced protection. Jake Dunning, a senior research fellow at the University of Oxford and member of the World Health Organization’s mpox emergency committee, pointed out that vaccines may still effectively prime the immune system to respond quickly if exposed to the virus.
“Vaccines designed to protect people against smallpox and mpox may differ in their ability to stimulate different parts of the immune system, including long-term ‘memory’ functions,” said Dunning, adding that more research is needed to assess the vaccine’s long-term efficacy.
Larger studies involving diverse populations, such as children, pregnant women, and people with HIV, are necessary to better understand how the vaccine performs over time, according to Alexis Robert, a research fellow at the London School of Hygiene and Tropical Medicine.
Despite the recent findings, experts noted that mpox case numbers remain low in North America and Europe since the outbreak was brought under control in 2022 through targeted public health measures. However, a new strain of the virus has emerged in the Democratic Republic of the Congo, causing concern among health officials as cases and deaths continue to rise across Africa.
Latest
Flash Floods Devastate Thai Elephant Sanctuary, Killing Two Elephants and Forcing Evacuations
Latest
Severe Drought Causes Record Low Water Levels in Brazil’s Negro River
Latest
Oxford Scientists Develop First Ovarian Cancer Vaccine in Groundbreaking Research
-
Business8 months ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business8 months ago
Recent Developments in Small Business Taxes
-
Politics8 months ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business6 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business7 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology8 months ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics8 months ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Technology8 months ago
Recent Developments in AI Ethics in America